Analysts Set Eton Pharmaceuticals, Inc. (NASDAQ:ETON) PT at $29.67

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has received a consensus recommendation of “Hold” from the five analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $29.6667.

A number of analysts have recently weighed in on ETON shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen upgraded Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, September 26th. Finally, Zacks Research upgraded Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 7th.

Eton Pharmaceuticals Trading Down 11.7%

NASDAQ ETON opened at $16.90 on Monday. Eton Pharmaceuticals has a 52 week low of $8.43 and a 52 week high of $23.00. The company has a 50 day moving average price of $18.81 and a 200 day moving average price of $17.07. The company has a quick ratio of 1.16, a current ratio of 1.77 and a debt-to-equity ratio of 1.14. The firm has a market cap of $453.26 million, a PE ratio of -67.60 and a beta of 1.12.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Thursday, November 6th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.20). The firm had revenue of $22.46 million during the quarter, compared to analyst estimates of $20.47 million. Eton Pharmaceuticals had a negative net margin of 9.50% and a negative return on equity of 11.18%. As a group, sell-side analysts forecast that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.

Insider Buying and Selling

In other Eton Pharmaceuticals news, CFO James R. Gruber sold 2,631 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $16.02, for a total transaction of $42,148.62. Following the sale, the chief financial officer owned 204,753 shares of the company’s stock, valued at approximately $3,280,143.06. The trade was a 1.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 16.03% of the stock is owned by company insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC grew its stake in shares of Eton Pharmaceuticals by 61.9% during the 1st quarter. Acadian Asset Management LLC now owns 402,428 shares of the company’s stock worth $5,219,000 after purchasing an additional 153,923 shares during the period. Cubist Systematic Strategies LLC lifted its stake in shares of Eton Pharmaceuticals by 138.7% in the 1st quarter. Cubist Systematic Strategies LLC now owns 103,200 shares of the company’s stock valued at $1,340,000 after purchasing an additional 59,961 shares during the period. PDT Partners LLC purchased a new stake in Eton Pharmaceuticals during the first quarter worth $334,000. Jacobs Levy Equity Management Inc. purchased a new stake in Eton Pharmaceuticals during the first quarter worth $704,000. Finally, Anchor Capital Advisors LLC grew its position in Eton Pharmaceuticals by 45.7% during the second quarter. Anchor Capital Advisors LLC now owns 87,661 shares of the company’s stock valued at $1,249,000 after buying an additional 27,482 shares during the period. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.